Same-session KERARINGS and CXL procedure is effective

Article

Combined use of intracorneal ring segments (KERARINGS) and corneal collagen cross-linking (CXL) in a single session is more effective than performing the procedure in two sessions

A recent study, published in the British Journal of Ophthalmology, has proved that the combined use of intracorneal ring segments (KERARINGS) and corneal collagen cross-linking (CXL) in a single session is more effective than performing the procedure in two sessions.

Professor Tamer M El-Raggal, Magrabi Eye Hospital, Cairo, Egypt, conducted the prospective, comparative study in 16 eyes of 10 patients with progressive mild to moderate keratoconus.

The patients were randomly split into two groups. In the first group, 9 eyes underwent KERARINGS insertion, then CXL 6 months later. The second group involved seven eyes that received both procedures on the same day. A femtosecond laser (Intralase FS 60) was used for channel creation.

Both groups saw a significant improvement in uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA). But same day combination treatment group experienced a more statistically significant decrease in keratometric values.

It was found that both KERARINGS and CXL can be carried out safely in one or two sessions. However, the single-session procedure proved more efficient and successful in improving the corneal shape.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.